Hardean E. Achneck, M.D. ’05, has been named chief medical officer (CMO) at Hemostemix, a clinical-stage autologous cell therapy company based in Toronto. As CMO, Achneck will lead and implement the company's multinational clinical research programs and oversee all medical affairs activities.

Achneck, a graduate of Yale College as well as the School of Medicine, was an assistant professor of surgery and pathology at the Duke University School of Medicine, and of cardiovascular and metabolic disorders at Duke-National University of Singapore. He brings more than a decade of clinical research experience across various therapeutic areas to the position. Prior to this promotion, he was vice president of clinical research and operations at Hemostemix. In that role, he was spearheading the implementation and enhancement of Hemostemix's international, multicenter, phase 2 clinical trial of ACP-01, its lead product for critical limb ischemia. He also coordinated successful regulatory submissions in Canada, South Africa and the United States.